Ai-Wei Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ai-Wei Tang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Siobhan Quenby
Warwick Medical School University of Warwick Coventry UK
5 shared publications - Mark A. Turner
University of Liverpool, Liverpool, UK
2 shared publications Ian Greer
Faculty of Health & Life Sciences, University of Liverpool, Foundation Building, Liverpool L69 7ZX, UK
1 shared publicationJo Drury
School of Reproductive and Developmental Medicine, University of Liverpool, Liverpool Women's Hospital, Crown Street, Liverpool, L8 7SS, UK
1 shared publication- Josephine A. Drury
Department of Women's and Children's Health, University of Liverpool, UK
1 shared publication Z. Alfirevic
Institute of Translational Medicine, Department for Women's and Children's Health , University of Liverpool , Liverpool L8 7SS , UK
1 shared publication
Latest Publications
- 1 June 2013
- Published by SAGE Publications in Obstetric Medicine
- Vol. 6 (2) , 64-71
A systematic review on the use of new anticoagulants in pregnancy
New anticoagulants such as direct factor Xa inhibitors and direct thrombin inhibitors have been recently developed, but their experience in pregnancy is limited. This review therefore aims to systematically search for studies on the use of these newer anticoagulants in pregnancy and the puerperal period. Searches were performed on electronic databases MEDLINE (from 1966), EMBASE (from 1974) and the Cochrane Library, until October 2011 using terms of ‘pregnancy’, ‘puerperium’, ‘breastfeeding’ and names of specific anticoagulants. The search yielded 561 citations and 11 studies (10 on fondaparinux, 1 on ximelagatran) were included. Newer anticoagulants (fondaparinux, hirudin and argatroban) on the limited evidence appear not to have adverse pregnancy outcomes, but there is currently no experience of new oral anticoagulants (rivaroxaban, apixaban, betrixaban or dabigatran) use in pregnancy. There is a need for reporting on new oral anticoagulation use in pregnancy to provide more information about the safety and risks to the fetus in utero.
- 1 June 2013
- Published by SAGE Publications in Obstetric Medicine
- Vol. 6 (2) , 64-71
A systematic review on the use of new anticoagulants in pregnancy
New anticoagulants such as direct factor Xa inhibitors and direct thrombin inhibitors have been recently developed, but their experience in pregnancy is limited. This review therefore aims to systematically search for studies on the use of these newer anticoagulants in pregnancy and the puerperal period. Searches were performed on electronic databases MEDLINE (from 1966), EMBASE (from 1974) and the Cochrane Library, until October 2011 using terms of ‘pregnancy’, ‘puerperium’, ‘breastfeeding’ and names of specific anticoagulants. The search yielded 561 citations and 11 studies (10 on fondaparinux, 1 on ximelagatran) were included. Newer anticoagulants (fondaparinux, hirudin and argatroban) on the limited evidence appear not to have adverse pregnancy outcomes, but there is currently no experience of new oral anticoagulants (rivaroxaban, apixaban, betrixaban or dabigatran) use in pregnancy. There is a need for reporting on new oral anticoagulation use in pregnancy to provide more information about the safety and risks to the fetus in utero.
- 1 April 2013
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 97 (2) , 183-185
A rapid, reliable method for uNK cell density estimation
- 1 April 2013
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 97 (2) , 183-185
A rapid, reliable method for uNK cell density estimation
- Open Access
- 25 May 2011
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 26 (8) , 1971-1980
Natural killer cells and pregnancy outcomes in women with recurrent miscarriage and infertility: a systematic review
Peripheral natural killer (pNK) and uterine NK (uNK) cells have been associated with reproductive failure. We systematically reviewed the literature to assess whether numbers or activity of pNK or uNK cells predicted subsequent pregnancy and outcome. We searched the electronic MEDLINE database from 1950 to April 2010 for relevant publications by using MeSH terms ‘natural killer cells’, ‘reproduction’ and ‘pregnancy complications’. We included studies that measured pre-pregnancy pNK and uNK cell numbers or activity in women with recurrent miscarriage (RM) or infertility, and reported subsequent pregnancy outcomes of miscarriage or failure to conceive after assisted reproductive technology (ART). The search identified 783 publications and 12 fulfilled the inclusion criteria. There were too few women entered into the observational studies to assess whether high pNK cell percentages or activity predicted subsequent miscarriage in women with idiopathic RM (numbers: n = 32, OR 17, 95% CI 0.82–350.6, activity: n = 92, OR 2.51, 95% CI 0.16–40.29), or implantation failure (n = 203, OR 1.35, 95% CI 0.28–6.46), or miscarriage in infertile women after ART (n = 79, OR 2.48, 95% CI 0.50–12.32). Similarly, the studies of uNK cells were not large enough to assess whether abnormal uNK cell density predicted subsequent miscarriage in women with idiopathic RM (n = 72, OR 1.33, 95% CI 0.16–11.11). None of the uNK cell studies in women with infertility reported pregnancy outcomes dichotomized for uNK cell numbers. The prognostic value of measuring pNK or uNK cell parameters remains uncertain. More studies are needed to confirm or refute the role of NK cell assessments as a predictive test for screening women who may benefit from immunotherapy.
- 25 May 2011
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 26 (8) , 1971-1980
Open AccessNatural killer cells and pregnancy outcomes in women with recurrent miscarriage and infertility: a systematic review
Peripheral natural killer (pNK) and uterine NK (uNK) cells have been associated with reproductive failure. We systematically reviewed the literature to assess whether numbers or activity of pNK or uNK cells predicted subsequent pregnancy and outcome. We searched the electronic MEDLINE database from 1950 to April 2010 for relevant publications by using MeSH terms ‘natural killer cells’, ‘reproduction’ and ‘pregnancy complications’. We included studies that measured pre-pregnancy pNK and uNK cell numbers or activity in women with recurrent miscarriage (RM) or infertility, and reported subsequent pregnancy outcomes of miscarriage or failure to conceive after assisted reproductive technology (ART). The search identified 783 publications and 12 fulfilled the inclusion criteria. There were too few women entered into the observational studies to assess whether high pNK cell percentages or activity predicted subsequent miscarriage in women with idiopathic RM (numbers: n = 32, OR 17, 95% CI 0.82–350.6, activity: n = 92, OR 2.51, 95% CI 0.16–40.29), or implantation failure (n = 203, OR 1.35, 95% CI 0.28–6.46), or miscarriage in infertile women after ART (n = 79, OR 2.48, 95% CI 0.50–12.32). Similarly, the studies of uNK cells were not large enough to assess whether abnormal uNK cell density predicted subsequent miscarriage in women with idiopathic RM (n = 72, OR 1.33, 95% CI 0.16–11.11). None of the uNK cell studies in women with infertility reported pregnancy outcomes dichotomized for uNK cell numbers. The prognostic value of measuring pNK or uNK cell parameters remains uncertain. More studies are needed to confirm or refute the role of NK cell assessments as a predictive test for screening women who may benefit from immunotherapy.
- 1 December 2010
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 22 (6) , 446-451
Recent thoughts on management and prevention of recurrent early pregnancy loss
To provide an overview of the latest views and evidence available to clinicians managing couples with recurrent early pregnancy loss (RPL). RPL is a heterogeneous condition associated with many pathologies, none of which is found in more than 50% of couples after routine investigations. The recommended treatment of low-dose aspirin and heparin in women with antiphospholipid syndrome has a weak evidence base. Recent randomized controlled trials (RCTs) of low-dose aspirin and heparin have failed to find an improvement in live birth rates, even in the presence of thrombophilia. Although parental karyotypic abnormalities are associated with RPL, conservative management of such couples may be optimal. Observational studies of hysteroscopic metroplasty have promising results, but evidence from RCTs is awaited. Progestogen therapy may improve pregnancy outcomes, but further RCTs are needed. Immunological factors are thought to be important in idiopathic RPL. Research is focused on natural killer cells and cytokines in influencing implantation as potential therapeutic treatments. Currently, RCTs have not substantiated a benefit for immunotherapy. Management of RPL remains challenging, with many controversial issues regarding the underlying pathophysiology. Improvements in live birth rates in subsequent pregnancies have not been found in RCTs of treatment for most of the associated conditions. All women can be offered supportive care in subsequent pregnancies. Empirical treatment is widely used in idiopathic RPL. A better option may be to encourage women to participate in high-quality and methodologically sound studies to guide optimal management.
- 1 December 2010
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 22 (6) , 446-451
Recent thoughts on management and prevention of recurrent early pregnancy loss
To provide an overview of the latest views and evidence available to clinicians managing couples with recurrent early pregnancy loss (RPL). RPL is a heterogeneous condition associated with many pathologies, none of which is found in more than 50% of couples after routine investigations. The recommended treatment of low-dose aspirin and heparin in women with antiphospholipid syndrome has a weak evidence base. Recent randomized controlled trials (RCTs) of low-dose aspirin and heparin have failed to find an improvement in live birth rates, even in the presence of thrombophilia. Although parental karyotypic abnormalities are associated with RPL, conservative management of such couples may be optimal. Observational studies of hysteroscopic metroplasty have promising results, but evidence from RCTs is awaited. Progestogen therapy may improve pregnancy outcomes, but further RCTs are needed. Immunological factors are thought to be important in idiopathic RPL. Research is focused on natural killer cells and cytokines in influencing implantation as potential therapeutic treatments. Currently, RCTs have not substantiated a benefit for immunotherapy. Management of RPL remains challenging, with many controversial issues regarding the underlying pathophysiology. Improvements in live birth rates in subsequent pregnancies have not been found in RCTs of treatment for most of the associated conditions. All women can be offered supportive care in subsequent pregnancies. Empirical treatment is widely used in idiopathic RPL. A better option may be to encourage women to participate in high-quality and methodologically sound studies to guide optimal management.
- 9 September 2010
- Published by Cambridge University Press (CUP)
- p. 75-84
Uterine natural killer cells and reproduction
The majority of ectopic pregnancies occur within the Fallopian tube, with most implanted in the ampullary region. A number of risk factors have been identified for ectopic pregnancy. Transvaginal ultrasound (TVU) has now become the diagnostic technique of choice for ectopic pregnancy. Historically, laparotomy with salpingectomy was the standard treatment for ectopic pregnancy. Laparoscopic surgery has been shown to be superior to laparotomy, making it the surgical approach of choice. A number of drugs have been used for the treatment of ectopic pregnancy including potassium chloride, prostaglandins, hyperosmolar glucose, mifepristone and actinomycin D. However, the most commonly used drug in clinical practice for the treatment of ectopic pregnancy is methotrexate. The reported success rates for expectant management range between 48-100%. Subsequent hysterosalpingography has shown patency for the affected tube in up to 93% of cases of ectopic pregnancy managed expectantly.
- 9 September 2010
- Published by Cambridge University Press (CUP)
- p. 75-84
Uterine natural killer cells and reproduction
The majority of ectopic pregnancies occur within the Fallopian tube, with most implanted in the ampullary region. A number of risk factors have been identified for ectopic pregnancy. Transvaginal ultrasound (TVU) has now become the diagnostic technique of choice for ectopic pregnancy. Historically, laparotomy with salpingectomy was the standard treatment for ectopic pregnancy. Laparoscopic surgery has been shown to be superior to laparotomy, making it the surgical approach of choice. A number of drugs have been used for the treatment of ectopic pregnancy including potassium chloride, prostaglandins, hyperosmolar glucose, mifepristone and actinomycin D. However, the most commonly used drug in clinical practice for the treatment of ectopic pregnancy is methotrexate. The reported success rates for expectant management range between 48-100%. Subsequent hysterosalpingography has shown patency for the affected tube in up to 93% of cases of ectopic pregnancy managed expectantly.
- Open Access
- 10 November 2009
- Published by Springer Nature in Trials
- Vol. 10 (1) , 102
Prednisolone Trial: Study protocol for a randomised controlled trial of prednisolone for women with idiopathic recurrent miscarriage and raised levels of uterine natural killer (uNK) cells in the endometrium
Idiopathic recurrent miscarriage is defined as 3 consecutive pregnancy losses with no contributing features found on investigations. At present there are no treatments of proven efficacy for idiopathic recurrent miscarriage. Uterine natural killer (uNK) cells, the most predominant leucocyte in the endometrium are adjacent to foetal trophoblast cells and thought to be involved in implantation. The exact mechanisms of how uNK cells affect implantation are not clear but are probably through the regulation of angiogenesis. Multiple studies have shown an association between high density of uterine natural killer cells and recurrent miscarriage. We have shown that prednisolone reduces the number of uNK cells in the endometrium. The question remains as to whether reducing the number of uNK cells improves pregnancy outcome.
- 10 November 2009
- Published by Springer Nature in Trials
- Vol. 10 (1) , 102
Open AccessPrednisolone Trial: Study protocol for a randomised controlled trial of prednisolone for women with idiopathic recurrent miscarriage and raised levels of uterine natural killer (uNK) cells in the endometrium
Idiopathic recurrent miscarriage is defined as 3 consecutive pregnancy losses with no contributing features found on investigations. At present there are no treatments of proven efficacy for idiopathic recurrent miscarriage. Uterine natural killer (uNK) cells, the most predominant leucocyte in the endometrium are adjacent to foetal trophoblast cells and thought to be involved in implantation. The exact mechanisms of how uNK cells affect implantation are not clear but are probably through the regulation of angiogenesis. Multiple studies have shown an association between high density of uterine natural killer cells and recurrent miscarriage. We have shown that prednisolone reduces the number of uNK cells in the endometrium. The question remains as to whether reducing the number of uNK cells improves pregnancy outcome.